Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a β3‑adrenergic receptor agonist presented as a tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is indicated for conditions related to overactive bladder, a disorder of detrusor muscle activity.

- Overactive bladder: reduces urinary urgency and frequency, increasing bladder capacity. - Urinary urgency: alleviates sudden strong need to void. - Urinary frequency: decreases the number of daytime voids.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient head pain. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation. - Urinary tract infection: mild infection symptoms.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Severe hypertension: markedly high blood pressure requiring medical attention. - Tachycardia: rapid heart rate. - Angioedema: swelling of face, lips or throat. - Anaphylaxis: rare severe allergic reaction.

Before initiating therapy, consider the following precautions.

- Assess blood pressure: monitor baseline and periodic readings. - Review renal function: adjust use in severe impairment. - Avoid in uncontrolled hypertension: contraindicated. - Caution in elderly: may be more sensitive to adverse effects. - Evaluate concomitant medications: potential for interactions. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Mirabegron may interact with several drug classes; review patient medication lists.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase mirabegron exposure and risk of side effects. - Antihypertensive agents: additive blood‑pressure‑lowering effects can cause hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may affect fluid balance and blood pressure. - Other β‑adrenergic agents: potential additive cardiovascular effects. - Anticholinergics: may reduce the therapeutic benefit of mirabegron.